Science Explorer Back to mapMap
Topic · Biochemistry

Eicosanoids and Hypertension Pharmacology

Eicosanoids and Hypertension Pharmacology is a research topic within Biochemistry. Science Explorer counts 36k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the metabolism, function, and therapeutic implications of arachidonic acid derivatives, particularly epoxyeicosatrienoic acids (EETs), cytochrome P450 enzymes, and soluble epoxide hydrolase. The research covers their roles in cardiovascular function, inflammation, hypertension, and potential as therapeutic targets.

  • Arachidonic Acid
  • Epoxyeicosatrienoic Acids
  • Cytochrome P450
  • Soluble Epoxide Hydrolase
  • Cardiovascular Function
  • Inflammation
  • Hypertension
  • Eicosanoids
  • Metabolism
  • Therapeutic Target
Research works
36k
fractional, since 1950
In the world top 10%
3.6k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-5%
the tick is no change
Largest producer
China
32% of the 10 largest, 2022-now
Eicosanoids and Hypertension Pharmacology

Which countries lead Eicosanoids and Hypertension Pharmacology research?

By volume, China and the United States publish the most (709 and 707 works in 2022-now).

By volume, 2022-now

  1. 1 China 709 works
  2. 2 United States 707 works
  3. 3 Russia 138 works
  4. 4 Japan 137 works
  5. 5 India 135 works
  6. 6 Germany 109 works
  7. 7 Italy 85 works
  8. 8 United Kingdom 77 works
  9. 9 South Korea 76 works
  10. 10 Spain 61 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 31.7%United States: 31.6%Russia: 6.2%Japan: 6.1%6 others listed: 24.3%32%largest
China709 · 31.7%United States707 · 31.6%Russia138 · 6.2%Japan137 · 6.1%6 others listed543 · 24.3%

Shares of the rows listed above, not of the whole node.

Which institutions lead Eicosanoids and Hypertension Pharmacology research?

By volume in 2022-now, Russian Academy of Sciences publishes the most Eicosanoids and Hypertension Pharmacology research, followed by Harvard University and University of California, Davis.

Who are the leading researchers in Eicosanoids and Hypertension Pharmacology?

The most-cited researchers publishing on Eicosanoids and Hypertension Pharmacology include George Davey Smith, Walter Churchill Willett and Guido Kroemer.

  1. 1 George Davey Smith United Kingdom 435k citations
  2. 2 Walter Churchill Willett United States 411k citations
  3. 3 Guido Kroemer France 386k citations
  4. 4 John J.V. McMurray United Kingdom 349k citations
  5. 5 Hermann Brenner Germany 343k citations
  6. 6 Shizuo Akira Japan 342k citations
  7. 7 Emelia J. Benjamin United States 341k citations
  8. 8 Jun Wang China 340k citations
  9. 9 Giuseppe Remuzzi Italy 328k citations
  10. 10 Matthias Egger Switzerland 326k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Eicosanoids and Hypertension Pharmacology?

The most cited paper in Eicosanoids and Hypertension Pharmacology is "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor" (Richard M. J. Palmer, Anthony G. Ferrige, Salvador Moncada, 1987), with 10,799 citations. Next come "Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs" (8,642) and "Decision-Making in a Fuzzy Environment" (6,821).

Most cited papers
#PaperReleasedCitations
1 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor Richard M. J. Palmer, Anthony G. Ferrige, Salvador Moncada · Nature Jun 1987 10,799
2 Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs John Robert Vane · Nature New Biology Jun 1971 8,642
3 Decision-Making in a Fuzzy Environment Richard Bellman, L. A. Zadeh · Management Science Open access Dec 1970 6,821
4 The L-Arginine-Nitric Oxide Pathway Franklin H. Epstein, Salvador Moncada, Annie Higgs · New England Journal of Medicine 30 Dec 1993 6,737
5 Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. L J Ignarro, Georgette M. Buga, Keith S. Wood et al. · Proceedings of the National Academy of Sciences Open access Dec 1987 5,093
All 99 most cited papers, with filters and sorting

Where is Eicosanoids and Hypertension Pharmacology research done?

The largest centres of Eicosanoids and Hypertension Pharmacology research in 2022-now are Beijing (China), Shanghai (China), Moscow (Russia) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Davis.

Largest cities, 2022-now

  1. 1 BeijingChina 80 works
  2. 2 ShanghaiChina 48 works
  3. 3 MoscowRussia 46 works
  4. 4 TokyoJapan 42 works
  5. 5 GuangzhouChina 40 works
  6. 6 WuhanChina 33 works
  7. 7 NanjingChina 30 works
  8. 8 SeoulSouth Korea 30 works
  9. 9 LondonUnited Kingdom 26 works
  10. 10 DavisUnited States 26 works

Where it is the local speciality

  1. DavisUS · 26.2 works12×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Eicosanoids and Hypertension Pharmacology than the world average.

See Eicosanoids and Hypertension Pharmacology on the map

Where is the best place to study Eicosanoids and Hypertension Pharmacology?

Among universities, judged by research, Harvard University, University of California, Davis and Karolinska Institutet score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.14%fractional works in this field (log) →share of work in the world top 10% →Wuhan UniversityHarvard UniversityKarolinska InstitutetUniversity of Califo…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 80.022.3%3.3×27 -31.7%
2University of California, DavisUnited States 62.110.1%11.9×25 -23.9%
3Karolinska InstitutetSweden 53.719.3%6.4×10 -31.0%
4Wuhan UniversityChina 52.836.1%2.4×9 +8.4%
5University of MichiganUnited States 48.215.1%2.7×11 +29.2%
6Chongqing Medical UniversityChina 47.818.8%6.8×10 +19.4%
7Vanderbilt UniversityUnited States 47.519.8%5.1×10 -38.5%
8The Ohio State UniversityUnited States 44.923.8%2.8×9 +75.2%
9University of AlbertaCanada 43.66.9%5.9×13 -3.5%
10Huazhong University of Science and TechnologyChina 41.419.2%2.7×13 -16.6%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Eicosanoids and Hypertension Pharmacology, country by country

Is Eicosanoids and Hypertension Pharmacology research growing?

Output in 2022-2025 was 5% lower than in 2018-2021, peaking in 2008.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Eicosanoids and Hypertension Pharmacology as a percentage of every work published that year, 0.013% in 2024.

still counting0.050%0.10%0.15%Eicosanoids and Hypertension Pharmacology0.013% in 202519801990200020102020

Fractional works of Eicosanoids and Hypertension Pharmacology over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Eicosanoids and Hypertension Pharmacology10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Eicosanoids and Hypertension Pharmacology. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.